Mathers Edward T 4

What Happened
Edward T. Mathers, a director of Trevi Therapeutics (TRVI), received a grant of derivative securities—an option award covering 35,000 shares—on June 3, 2026. The award is reported at $0.00 per share (typical for an option grant entry on Form 4); no cash was paid on grant and no shares were exercised or sold in this transaction. This is an award/grant (transaction code A), generally a routine form of director compensation rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-03 (reported in Form 4 filed 2026-06-04). Transaction code: A (award/grant). Price shown: $0.00 (derivative option grant).
• Amount: 35,000 option share equivalents granted. Reported cash value on the Form 4: $0 (derivative instrument).
• Vesting: Per footnote F1, the option vests in full on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Timeliness: Filing appears timely (transaction 2026-06-03; Form 4 filed 2026-06-04).

Context
This was a grant of options (a derivative award), not an exercise or sale—no immediate proceeds or share transfers occurred. Such option awards are commonly used to compensate directors; they do not by themselves indicate buying or selling pressure. Vesting is service-based and may accelerate at the next annual meeting per the footnote.